WO2011126327A3 - Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof - Google Patents

Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof Download PDF

Info

Publication number
WO2011126327A3
WO2011126327A3 PCT/KR2011/002458 KR2011002458W WO2011126327A3 WO 2011126327 A3 WO2011126327 A3 WO 2011126327A3 KR 2011002458 W KR2011002458 W KR 2011002458W WO 2011126327 A3 WO2011126327 A3 WO 2011126327A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
pharmaceutical composition
sustained
active ingredient
levodropropizine
Prior art date
Application number
PCT/KR2011/002458
Other languages
French (fr)
Other versions
WO2011126327A2 (en
Inventor
Ho-Seong Jeon
Yong-Kwan Shin
Dae-Woong Ko
Su-Bin Im
Kang-Min Kim
Jae-Keol Rhee
Sung-Hoon Kam
Original Assignee
Hyundai Pharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100032791A external-priority patent/KR101246553B1/en
Priority claimed from KR1020100095142A external-priority patent/KR101272470B1/en
Application filed by Hyundai Pharm Co., Ltd. filed Critical Hyundai Pharm Co., Ltd.
Publication of WO2011126327A2 publication Critical patent/WO2011126327A2/en
Publication of WO2011126327A3 publication Critical patent/WO2011126327A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Abstract

Disclosed is a sustained-release pharmaceutical composition comprising mosapride or levodropropizine as an active ingredient, a method of preparing the same, and a pharmaceutical composition with dual release property comprising a sustained-release part and an immediate release part respectively comprising the active ingredient. The sustained-release pharmaceutical composition may constantly release drugs despite change in internal organ movement state of a subject, and it may constantly release the active ingredient even if a long time passes after administration, and thus, it may sufficiently deliver drugs only with single dose or two doses per day. And, since the pharmaceutical composition with dual release property has an immediate part and a sustained-release part exhibiting independent release properties, it may simultaneously increase rapid pharmaceutical effect and convenience for internal use, and improved treatment effect may also be expected due to improved the dissolution stability.
PCT/KR2011/002458 2010-04-09 2011-04-07 Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof WO2011126327A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0032791 2010-04-09
KR1020100032791A KR101246553B1 (en) 2010-04-09 2010-04-09 Sustained-release composition and process for producing the same
KR10-2010-0095142 2010-09-30
KR1020100095142A KR101272470B1 (en) 2010-09-30 2010-09-30 Immediate-release and sustained-release pharmaceutical composition comprising levodropropizine

Publications (2)

Publication Number Publication Date
WO2011126327A2 WO2011126327A2 (en) 2011-10-13
WO2011126327A3 true WO2011126327A3 (en) 2012-02-02

Family

ID=44763424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002458 WO2011126327A2 (en) 2010-04-09 2011-04-07 Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof

Country Status (1)

Country Link
WO (1) WO2011126327A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130117128A (en) * 2012-04-17 2013-10-25 한국유나이티드제약 주식회사 Sustained release tablets containing levodropropizine and manufacturing method for the same
WO2014142616A1 (en) 2013-03-15 2014-09-18 한국유나이티드제약 주식회사 Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets
US6132771A (en) * 1996-01-08 2000-10-17 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20060018934A1 (en) * 2002-08-05 2006-01-26 Navin Vaya Novel drug delivery system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6132771A (en) * 1996-01-08 2000-10-17 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets
US20060018934A1 (en) * 2002-08-05 2006-01-26 Navin Vaya Novel drug delivery system
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats

Also Published As

Publication number Publication date
WO2011126327A2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
WO2008146178A3 (en) A novel tablet dosage form
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2012020097A3 (en) Use of binders for manufacturing storage stable formulations
MX2019007956A (en) Self-regulated release of active pharmaceutical ingredient.
JP2015523407A5 (en)
WO2011115969A3 (en) Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
EA201590449A1 (en) ORAL PREPARED MEDICINE COMPOSITION
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
WO2012007159A3 (en) Novel gastro-retentive dosage forms
AR084865A1 (en) FAST DISINTEGRATION PREPARATION, DISPERSABLE COMPRESSED BY ORAL ROUTE
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX340188B (en) Manufacturing of active-free granules and tablets comprising the same.
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
EP2842938A4 (en) Novel beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
MXPA06000760A (en) Stable pharmaceutical composition containing carisoprodol and meloxicam.
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
CL2013001707A1 (en) Non-inflatable controlled-release tablet for oral administration of an active ingredient that is in an erodible polymeric matrix and diffusion-release system formed by retardant polymer and matrix-forming copolymer; method for preparing a pharmaceutical composition; Use to prepare a medicine.
WO2013127539A3 (en) Pharmaceutical formulation containing flupirtin
WO2016193454A3 (en) Dosage of naloxone
TR201005911A2 (en) A drug formulation with improved dissolution profile.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766178

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11766178

Country of ref document: EP

Kind code of ref document: A2